Haystack Oncology is a technology company.
Haystack Oncology has raised $56.0M across 1 funding round.
Haystack Oncology has raised $56.0M in total across 1 funding round.
Haystack Oncology has raised $56.0M in total across 1 funding round.
Haystack Oncology's investors include Andreessen Horowitz, Catalio Capital, Dimension Capital, VZVC, Mei Z..
Haystack Oncology is a precision oncology company developing Haystack Duo™ (now Haystack MRD™), a tumor-informed liquid biopsy test for detecting minimal residual disease (MRD) through circulating tumor DNA (ctDNA) in blood.[1][2][3][5] It serves cancer patients post-surgery or treatment, clinicians, and biopharma partners by identifying low levels of residual, recurrent, or resistant cancer earlier than standard methods, enabling personalized therapy decisions to improve outcomes.[1][3][5] The platform starts with tissue-based whole-exome sequencing to create patient-specific mutation panels, delivering ultrasensitive detection via patented error-correction technology that checks both DNA strands for variants.[1][5] Following a $56 million Series A in 2021 and acquisition by Quest Diagnostics in 2023, Haystack benefits from Quest's scale, including 7,000 U.S. collection sites, pathology expertise, and EHR integration, accelerating broad clinical adoption.[3][4][5]
Haystack Oncology was co-founded in 2021 by cancer genomics pioneers Drs. Bert Vogelstein, Ken Kinzler, and Nick Papadopoulos from Johns Hopkins University's Ludwig Center at the Kimmel Cancer Center, alongside Joshua Cohen, CEO Dan Edelstein, and CTO Dr. Frank Holtrup.[1] Their idea stemmed from over two decades of research in liquid biopsy technologies, focusing on detecting trace ctDNA molecules—indicators of residual cancer post-treatment—that signal recurrence risk.[1][3][5] Catalio Capital initiated the company, supporting its launch with a $56 million Series A to expand the Haystack Duo™ platform.[1][2] Early traction built on the founders' transformative work in early cancer detection, leading to Quest Diagnostics' acquisition in April 2023, which integrated Haystack's tech into Quest's oncology portfolio for wider accessibility.[3][4]
Haystack stands out in MRD testing through:
Haystack rides the liquid biopsy and precision oncology wave, where MRD detection addresses a critical gap: surgery and adjuvant therapies often miss microscopic cancer remnants, leading to undetected recurrence in most early-stage solid tumors.[2][3] Timing aligns with surging demand for ctDNA-based monitoring, fueled by advances in genomics and immunotherapy, enabling "right treatment, right time" personalization.[1][5] Market forces like aging populations, rising cancer incidence, and biopharma's need for therapeutic development tools favor Haystack, amplified by Quest's infrastructure to democratize high-sensitivity testing beyond research labs.[3][4][5] It influences the ecosystem by setting accuracy benchmarks, supporting clinical trials, and integrating with pathology/genomics workflows, potentially transforming post-treatment surveillance for millions.[1][3]
Post-acquisition, Haystack's trajectory points to rapid commercialization of Haystack MRD™, expanding into routine oncology workflows via Quest's network and prioritizing patient access.[3][5] Key trends like AI-enhanced sequencing, multi-cancer early detection, and combination therapies with MRD-guided interventions will shape its growth, alongside biopharma partnerships for drug monitoring.[1][5] Its influence may evolve from niche innovator to standard-of-care enabler, driving better survival rates through precise recurrence prediction—fulfilling the precision oncology vision that began with its founders' groundbreaking research.[1][3]
Haystack Oncology has raised $56.0M across 1 funding round. Most recently, it raised $56.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $56.0M Series A | Andreessen Horowitz, Catalio Capital, Dimension Capital, VZVC, Mei Z. |